In contrast, subjects receiving treatment with Cat‐PAD showed a trend toward downregulation of CRTh2 (P = 0.06) which was significant when comparing the change in MFI between subjects in the placebo vs active group (P = 0.047) (Figure 5). Here, PTGDR2 is linked to peripheral arterial disease.